CXCL5
edit |
Hemokin (C-X-C motiv) ligand 5 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Identifikatori | |||||||||||
Simboli | CXCL5; ENA-78; SCYB5 | ||||||||||
Vanjski ID | OMIM: 600324 HomoloGene: 88672 GeneCards: CXCL5 Gene | ||||||||||
| |||||||||||
Pregled RNK izražavanja | |||||||||||
podaci | |||||||||||
Ortolozi | |||||||||||
Vrsta | Čovek | Miš | |||||||||
Entrez | 6374 | n/a | |||||||||
Ensembl | ENSG00000163735 | n/a | |||||||||
UniProt | P42830 | n/a | |||||||||
RefSeq (mRNA) | NM_002994 | n/a | |||||||||
RefSeq (protein) | NP_002985 | n/a | |||||||||
Lokacija (UCSC) | Chr 4: 75.08 - 75.08 Mb | n/a | |||||||||
PubMed pretraga | [1] | n/a |
CXCL5, hemokin (C-X-C motiv) ligand 5 protein je kod ljudi kodiran CXCL5 genom.[1][2] CXCL5 protein je mali citokin iz CXC hemokin familije koji je takođe poznat kao epitelijalni neutrofil-aktivirajući peptid 78 (ENA-78). On se proizvodi nakon stimulacije ćelija sa inflamatornim citokinima interleukin-1 ili faktorom nekroze tumora-alfa.[3] CXCL5 ekspresija je takođe bila primećena u eosinofilima, i ona može biti inhibirana sa tip II interferonom IFN-γ.[4] Ovaj hemokin stimuliše hemotaksu neutrofila koji poseduje angiogene osobine. On pobuđuje te efekte putem interakcije sa hemokin receptorom CXCR2 na ćelijskoj površini.[4] CXCL5 gen je kodiran na četiri eksona. On je lociran na ljudskom hromozomu 4 zajedno sa nekoliko drugih CXC hemokin gena.[3][5] CXCL5 je bio impliciran u remodelovanje veznog tkiva.[4][6]
Reference
- ↑ Chang MS, McNinch J, Basu R, Simonet S (Nov 1994). „Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene”. J Biol Chem 269 (41): 25277–82. PMID 7929219.
- ↑ „Entrez Gene: CXCL5 chemokine (C-X-C motif) ligand 5”.
- ↑ 3,0 3,1 Chang MS, McNinch J, Basu R, Simonet S (1994). „Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene”. J. Biol. Chem. 269 (41): 25277–82. PMID 7929219. Arhivirano iz originala na datum 2007-03-13. Pristupljeno 2014-05-24.
- ↑ 4,0 4,1 4,2 Persson T, Monsef N, Andersson P, Bjartell A, Malm J, Calafat J, Egesten A (2003). „Expression of the neutrophil-activating CXC chemokine ENA-78/CXCL5 by human eosinophils”. Clin. Exp. Allergy 33 (4): 531–7. DOI:10.1046/j.1365-2222.2003.01609.x. PMID 12680872.
- ↑ O'Donovan N, Galvin M, Morgan JG (1999). „Physical mapping of the CXC chemokine locus on human chromosome 4”. Cytogenet. Cell Genet. 84 (1-2): 39–42. DOI:10.1159/000015209. PMID 10343098.
- ↑ Mire-Sluis, Anthony R.; Thorpe, Robin, ur. (1998). Cytokines (Handbook of Immunopharmacology). Boston: Academic Press. ISBN 0-12-498340-5.
Dodatna literatura
- Duchene J, Lecomte F, Ahmed S, Cayla C, Pesquero J, Bader M, Perretti M, Ahluwalia A (2007). „A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5.”. J. Immunol. 179 (7): 4849–56. PMID 17878384.
- Walz A, Schmutz P, Mueller C, Schnyder-Candrian S (1997). „Regulation and function of the CXC chemokine ENA-78 in monocytes and its role in disease.”. J. Leukoc. Biol. 62 (5): 604–11. PMID 9365115.
- Struyf S, Proost P, Van Damme J (2004). „Regulation of the immune response by the interaction of chemokines and proteases.”. Adv. Immunol. 81: 1–44. DOI:10.1016/S0065-2776(03)81001-5. PMID 14711052.
- Walz A, Burgener R, Car B, et al. (1992). „Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8.”. J. Exp. Med. 174 (6): 1355–62. DOI:10.1084/jem.174.6.1355. PMC 2119025. PMID 1744577.
- Power CA, Furness RB, Brawand C, Wells TN (1995). „Cloning of a full-length cDNA encoding the neutrophil-activating peptide ENA-78 from human platelets.”. Gene 151 (1-2): 333–4. DOI:10.1016/0378-1119(94)90682-3. PMID 7828901.
- Corbett MS, Schmitt I, Riess O, Walz A (1995). „Characterization of the gene for human neutrophil-activating peptide 78 (ENA-78).”. Biochem. Biophys. Res. Commun. 205 (1): 612–7. DOI:10.1006/bbrc.1994.2709. PMID 7999089.
- Koch AE, Kunkel SL, Harlow LA, et al. (1994). „Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis.”. J. Clin. Invest. 94 (3): 1012–8. DOI:10.1172/JCI117414. PMC 295150. PMID 8083342.
- Power CA, Clemetson JM, Clemetson KJ, Wells TN (1996). „Chemokine and chemokine receptor mRNA expression in human platelets.”. Cytokine 7 (6): 479–82. DOI:10.1006/cyto.1995.0065. PMID 8580362.
- Ahuja SK, Murphy PM (1996). „The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor.”. J. Biol. Chem. 271 (34): 20545–50. DOI:10.1074/jbc.271.34.20545. PMID 8702798.
- Keates S, Keates AC, Mizoguchi E, et al. (1997). „Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis.”. Am. J. Physiol. 273 (1 Pt 1): G75–82. PMID 9252512.
- Wuyts A, Proost P, Lenaerts JP, et al. (1998). „Differential usage of the CXC chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell-derived neutrophil attractant-78.”. Eur. J. Biochem. 255 (1): 67–73. DOI:10.1046/j.1432-1327.1998.2550067.x. PMID 9692902.
- Wyrick PB, Knight ST, Paul TR, et al. (1999). „Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil chemotaxis.”. J. Infect. Dis. 179 (4): 954–66. DOI:10.1086/314676. PMID 10068592.
- Wuyts A, Govaerts C, Struyf S, et al. (1999). „Isolation of the CXC chemokines ENA-78, GRO alpha and GRO gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms.”. Eur. J. Biochem. 260 (2): 421–9. DOI:10.1046/j.1432-1327.1999.00166.x. PMID 10095777.
- Hogaboam CM, Bone-Larson CL, Steinhauser ML, et al. (1999). „Novel CXCR2-dependent liver regenerative qualities of ELR-containing CXC chemokines.”. FASEB J. 13 (12): 1565–74. PMID 10463948.
- Luu NT, Rainger GE, Nash GB (2000). „Differential ability of exogenous chemotactic agents to disrupt transendothelial migration of flowing neutrophils.”. J. Immunol. 164 (11): 5961–9. PMID 10820279.
- Crane IJ, Wallace CA, McKillop-Smith S, Forrester JV (2000). „Control of chemokine production at the blood-retina barrier.”. Immunology 101 (3): 426–33. DOI:10.1046/j.0019-2805.2000.01105.x. PMC 2327097. PMID 11106948.
- Zhang C, Thornton MA, Kowalska MA, et al. (2001). „Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein/platelet factor 4 gene locus.”. Blood 98 (3): 610–7. DOI:10.1182/blood.V98.3.610. PMID 11468158.
- Chandrasekar B, Melby PC, Sarau HM, et al. (2003). „Chemokine-cytokine cross-talk. The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-kappa B pathway.”. J. Biol. Chem. 278 (7): 4675–86. DOI:10.1074/jbc.M207006200. PMID 12468547.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). „Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. DOI:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
Spoljašnje veze
- MeSH Platelet+factor+5
- p
- r
- u
| |||||||||||||||
| |||||||||||||||
| |||||||||||||||